School of Health Sciences, City, University of London, London, UK.
Department of Primary Care and Public Health, Brighton and Sussex Medical School, Brighton, UK.
Lancet Psychiatry. 2022 Feb;9(2):125-136. doi: 10.1016/S2215-0366(21)00398-9.
High numbers of patients discharged from psychiatric hospital care are readmitted within a year. Peer support for discharge has been suggested as an approach to reducing readmission post-discharge. Implementation has been called for in policy, however, evidence of effectiveness from large rigorous trials is missing. We aimed to establish whether peer support for discharge reduces readmissions in the year post-discharge.
We report a parallel, two-group, individually randomised, controlled superiority trial, with trial personnel masked to allocation. Patients were adult psychiatric inpatients (age ≥18 years) with at least one previous admission in the preceding 2 years, excluding those who had a diagnosis of any organic mental disorder, or a primary diagnosis of learning disability, an eating disorder, or drug or alcohol dependency, recruited from seven state-funded mental health services in England. Patients were randomly assigned (1:1) to the intervention (peer support plus care as usual) or control (care as usual) groups by an in-house, online randomisation service, stratified by site and diagnostic group (psychotic disorders, personality disorders, and other eligible non-psychotic disorders) with randomly permuted blocks of randomly varying length to conceal the allocation sequence and achieve the allocation ratio. The peer support group received manual-based, one-to-one peer support, focused on building individual strengths and engaging with activities in the community, beginning during the index admission and continuing for 4 months after discharge, plus care as usual. Care as usual consisted of follow-up by community mental health services within 7 days of discharge. The primary outcome was psychiatric readmission 12 months after discharge (number of patients readmitted at least once), analysed on an intention-to-treat basis. All patients were included in a safety analysis, excluding those who withdrew consent for use of their data. The trial is registered with the ISRCTN registry, ISRCTN10043328. The trial was complete at the time of reporting.
Between Dec 1, 2016, and Feb 8, 2019, 590 patients were recruited and randomly assigned, with 294 allocated to peer support (287 included in the analysis after withdrawals and loss to follow-up), and 296 to care as usual (291 in the analysis). Mean age was 39·7 years (SD 13·7; range 18-75). 306 patients were women, 267 were men, three were transgender, and two preferred not to say. 353 patients were White, 94 were Black, African, Caribbean, or Black British, 68 were Asian or Asian British, 48 were of mixed or multiple ethnic groups, and 13 were of other ethnic groups. In the peer support group, 136 (47%) of 287 patients were readmitted at least once within 12 months of discharge. 146 (50%) of 291 were readmitted in the care as usual group. The adjusted risk ratio of readmission was 0·97 (95% CI 0·82-1·14; p=0·68), and the adjusted odds ratio for readmission was 0·93 (95% CI 0·66-1·30; p=0·68). The unadjusted risk difference was 0·03 (95% CI -0·11 to 0·05; p=0·51) in favour of the peer support group. Serious adverse events were infrequent (67 events) and similar between groups (34 in the peer support group, 33 in the care as usual group). Threat to life (self-harm) was the most common serious adverse event (35 [52%] of 67 serious adverse events). 391 other adverse events were reported, with self-harm (not life threatening) the most common (189 [48%] of 391).
One-to-one peer support for discharge from inpatient psychiatric care, plus care as usual, was not superior to care as usual alone in the 12 months after discharge. This definitive, high-quality trial addresses uncertainty in the evidence base and suggests that peer support should not be implemented to reduce readmission post-discharge for patients at risk of readmission. Further research needs to be done to improve engagement with peer support in high-need groups, and to explore differential effects of peer support for people from different ethnic communities.
UK National Institute for Health Research.
大量从精神病院出院的患者在一年内再次入院。出院后的同伴支持已被提议作为降低出院后再入院率的一种方法。然而,政策已经呼吁实施这种方法,但缺乏来自大型严格试验的有效性证据。我们旨在确定出院后的同伴支持是否可以降低出院后一年内的再入院率。
我们报告了一项平行、两臂、个体随机对照优势试验,试验人员对分配情况进行了盲法处理。患者为成年精神病住院患者(年龄≥18 岁),在过去 2 年内至少有一次入院,不包括任何器质性精神障碍、学习障碍、原发性饮食障碍、药物或酒精依赖的诊断,从英国七个由国家资助的精神卫生服务机构招募。患者按照 1:1 的比例随机分配(1:1)到干预组(同伴支持加常规护理)或对照组(常规护理),采用内部在线随机分配服务,按地点和诊断组(精神病障碍、人格障碍和其他非精神病障碍)进行分层,随机排列长度随机变化的随机块,以掩盖分配序列并达到分配比例。同伴支持组接受基于手册的一对一同伴支持,重点是建立个人优势并参与社区活动,从入院期间开始,持续 4 个月,再加上常规护理。常规护理包括出院后 7 天内由社区心理健康服务部门进行随访。主要结局是出院后 12 个月的精神科再入院(至少再入院一次的患者人数),按意向治疗进行分析。所有患者均纳入安全性分析,不包括那些退出使用其数据的同意的患者。该试验在报告时已完成。
2016 年 12 月 1 日至 2019 年 2 月 8 日期间,共招募了 590 名患者,并随机分配,其中 294 名分配到同伴支持组(287 名在撤回和随访丢失后纳入分析),296 名分配到常规护理组(291 名在分析中)。平均年龄为 39.7 岁(标准差 13.7;范围 18-75)。306 名患者为女性,297 名患者为男性,3 名为跨性别者,2 名患者更喜欢不透露性别。353 名患者为白人,94 名患者为黑人、非洲人、加勒比人或黑人英国人,68 名患者为亚洲人或亚洲英国人,48 名患者为混合或多种族裔,13 名患者为其他族裔。在同伴支持组中,287 名患者中有 136 名(47%)在出院后 12 个月内至少再次入院一次。291 名患者中有 146 名(50%)在常规护理组中再次入院。再入院的调整风险比为 0.97(95%CI 0.82-1.14;p=0.68),再入院的调整优势比为 0.93(95%CI 0.66-1.30;p=0.68)。未调整的风险差异为 0.03(95%CI -0.11 至 0.05;p=0.51),有利于同伴支持组。严重不良事件(SAE)较少(67 例),且两组间相似(同伴支持组 34 例,常规护理组 33 例)。威胁生命(自残)是最常见的严重不良事件(67 例严重不良事件中的 35 例)。报告了 391 例其他不良事件,其中自残(无生命危险)最常见(391 例中的 189 例)。
从精神病住院护理中出院后的一对一同伴支持,加上常规护理,在出院后 12 个月内并不优于常规护理。这项明确的高质量试验解决了证据基础中的不确定性,并表明对于有再入院风险的患者,不应实施同伴支持以降低出院后的再入院率。需要进一步研究,以提高高危人群对同伴支持的参与度,并探索同伴支持对不同族裔社区人群的不同影响。
英国国家卫生研究院。